Immudyne Shows Clinical Data
Nov. 17, 2010 (GlobeNewswire) --
MUNICH, Germany, Nov. 17, 2010 (GLOBE NEWSWIRE) -- Immudyne, Inc. (Pink Sheets:IMMD) is pleased to announce that Sven Rohmann, MD, PhD presented clinical data on Immudyne's ultra pure beta glucan produced from yeast through a proprietary patented process, in both orally and topically administered forms.
Immudyne's ultra pure beta glucan, administered orally with a daily dosage of 7.5 mg was shown to prevent the reoccurrence of cancer in 100% of 26 study participants who were in remission at the initiation of the study, compared to a matched control group of 23 participants that experienced a reoccurrence rate of 22 %.
In another clinical study Immudyne's ultra pure beta glucan was administered orally with a daily dosage of 15 mg to terminally-ill cancer patients, who were described as having a life expectancy of three months or less. After three months 79.6% of the 54 participants were still living, compared to only 2.4% of the 45 participants in the control group. After six months 43% of the participants taking Immudyne's beta glucan were still living, compared to none of the control group.
Dr Rohmann commented that these studies and others point to the potential of a therapeutic regimen combining Immudyne's ultra pure beta glucan with traditional forms of cancer treatments.
Dr. Rohmann also described a clinical study of the effectiveness of Immudyne's two topical beta glucan products. Applied twice daily the Immudyne products reduced the number and intensity of wrinkles in the female study participants significantly. At the initiation of the study the women had an average appearance of 44 years, as determined by the average wrinkle score. By the end of the eight week study the women had an average appearance of 29 years.
Immudyne is a biotechnology company that possesses an array of patented processes for the extraction of beta glucan from yeast in the most pure form available. Immudyne's products are currently being used in the nutraceutical field to aid in immune system function, in skin creams to reduce the signs of aging, and in the animal feeds industry as a substitute for antibiotics. Immudyne's processing facilities are located in Florence, Kentucky. Its products are sold globally.
About Immudyne(R)
Immudyne manufactures, distributes and sells all-natural yeast beta glucan products for immune system support.
Immudyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.immudyne.com (currently being transformed)
Cautionary language regarding Forward-Looking Statements
Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates,""believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
CONTACT: Immudyne, Inc.
Mark McLaughlin
1-914-714-8901
MarkMcL@immudyne.com
Source: Globe Newswire (November 17, 2010 - 9:32 AM EST)
News by QuoteMedia
www.quotemedia.com
AI
